A Phase 3 interventional study of OTL-103 in Wiskott-Aldrich Syndrome, sponsored by Fondazione Telethon. Active, not recruiting at 2 sites in 2 countries. Open to participants aged Up to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-29.
Sponsored by Fondazione Telethon · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Wiskott-Aldrich Syndrome with a site in United States — 3 open to participants now, 6 under way, 1 of them phase 3. Wiskott-Aldrich Syndrome · United States.
Among the 29 studies in Wiskott-Aldrich Syndrome with a site in United States, this one is the 15th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2019, is one of 3 in phase 3, and was the 27th registered.
41 studies on the registry are indexed under Wiskott-Aldrich Syndrome; 4 are open to participants now.
Browse Wiskott-Aldrich Syndrome studies →3 of the 29 studies in Wiskott-Aldrich Syndrome with a site in United States are open now. Recruiting first, the newest first:
Paul Szabolcs · Sites in United States
Ages 2 mo–60 yrs
Paul Szabolcs · Sites in United States
Ages 2 mo–55 yrs
Paul Szabolcs · Sites in United States
Ages 5–45
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 2 Wiskott-Aldrich Syndrome studies recruiting now, none set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: Up to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 3 · Phase 4 2
First in 1995; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 20 across 29 interventional studies indexed under Wiskott-Aldrich Syndrome.
Median enrollment 24 across the 21 interventional studies, 158 across the 6 observational. Of the 22 that completed or were terminated, 10 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 29 have an industry lead sponsor. The 10 most frequent:
Fondazione Telethon is the lead sponsor of 12 studies on the registry; 3 are open to participants now.
Fondazione Telethon has 2 studies filed under Wiskott-Aldrich Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Wiskott-Aldrich Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01852370Paul SzabolcsSequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases | 2026-11 |
| NCT01962415Paul SzabolcsReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT | 2026-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies in Wiskott-Aldrich Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, single arm study to evaluate the cryopreserved formulation of OTL-103 Gene Therapy. OTL-103 consists of autologous CD34+ hematopoietic stem cells in which the gene encoding for the Wiskott-Aldrich Syndrome is introduced by means of a third generation lentiviral vector.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of WAS defined by genetic mutation and at least one of the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
OTL-103, Autologous CD34+ hematopoietic stem cells transduced ex vivo with a lentiviral vector encoding the human WAS gene
Genetic: OTL-103
Autologous hematopoietic stem cells collected from mobilized peripheral blood transduced ex vivo with a lentiviral vector encoding the WAS cDNA
Annualized rate of severe infections from 6 to 18 months after gene therapy compared with 1 year before gene therapy
Time frame: 18 months
Annualized rate of moderate and severe bleeding episodes up to 1 year after gene therapy compared with 1 year before gene therapy
Time frame: 12 months
Evaluation of the overall survival
Time frame: 36 months
Number of patients with Vector copy number (VCN)/cell > 0.1 measured in peripheral blood-derived CD3+ cells
Time frame: 2 years
Percentage of WAS protein expression increased from pre-treatment levels in lymphocytes
Time frame: 2 years
Percentage of WAS protein expression increased from pre-treatment levels in platelets
Time frame: 2 years
Number of participants with successful engraftment of OTL-103
Engraftment of of OTL-103 is measured by hematological reconstitution of an absolute neutrophil count \> 500 cell/ul
Time frame: 6 months
The number of subjects presenting with malignancies or abnormal clonal proliferation
Time frame: 2 years
Plan to share: No
Ran from Jan 2019 to primary completion in Mar 2024, 61 months.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione Telethon